A new study from Public Health Scotland has found no cases of cervical cancer among women who were fully vaccinated against HPV. This follows the launch of a human papillomavirus (HPV) immunization program for girls aged 12 to 13 in Scotland in 2008.
Research published Jan. 22 in the Journal of the National Cancer Institute concluded that the HPV vaccine is “highly effective” in preventing cervical cancer.
The promising findings from the study, conducted by Public Health Scotland (PHS) in collaboration with the Universities of Strathclyde and Edinburgh, could make a significant contribution to global cervical cancer prevention initiatives.
HPV, a prevalent virus spread primarily through sexual contact, is the leading cause of nearly all cases of cervical cancer and is the fourth most common cancer in women worldwide. The study, conducted by a team of seven researchers, said: “Our results confirm that the bivalent vaccine prevents the development of invasive cervical cancer when given at 12-13 years of age, even if the doses are given one month apart A dose or two would also be beneficial.”
“At older ages, three doses were needed to achieve a statistically significant vaccine effect. Women from poorer areas benefited more from vaccination than women from poorer areas.”
Although cervical cancer is largely preventable, it remains the second most common cancer in India, according to Indian government data.
In 2022, India launched Cervavac, the first locally developed HPV vaccine for the prevention of cervical cancer, produced by the Serum Institute of India (SII).
According to the latest estimates, about 125,000 women in India are diagnosed with cervical cancer every year, and more than 75,000 die from the disease. In India, about 83% of invasive cervical cancers are attributed to HPV 16 or 18.
How is the research conducted?
This observational study is based on population data from Scotland, using linked information from screening, immunization and cancer registries. The aim was to investigate how age, dose and socioeconomic status influence the development of invasive disease after injection of a bivalent vaccine.
Information on women born between 1 January 1988 and 5 June 1996 was retrieved from the Scottish Cervical Cancer Screening System in July 2020. This data is then linked to cancer registry records, immunization records and socioeconomic data. To analyze the incidence of invasive cervical cancer per 100,000 person-years and vaccine effectiveness according to vaccination status, age at vaccination, and socioeconomic status.
Research result
The study found no cases of invasive cancer were detected among vaccinated girls at age 12 or 13, regardless of the number of doses. The study found that vaccinated women aged 14 to 22 who had received three doses of the vaccine had significantly fewer cases than unvaccinated women – 3.2 cases per 100,000 compared with There are 8.4 cases among people.
The study also found that women in poorer areas have higher cancer rates than women in poorer areas. However, women from the most deprived areas also experienced significant reductions in cancer rates after three doses of the vaccine.
Follow us on Google news ,Twitter , and Join Whatsapp Group of thelocalreport.in
